Arguably the most exciting development for Gilead in 2025 will be the approval of lenacapavir, a long-acting (administered twice-yearly) therapy that has reported highly positive data from pivotal ...

We recently compiled a list of the 8 Best Humane Stocks to Invest in Now. In this article, we are going to take a look at ...

traded higher in the premarket on Thursday after the antiviral developer posted interim data from a Phase 1 trial for ABI-4334, an investigational therapy it develops with Gilead (NASDAQ ...

Kite Pharma is flying high with the addition of a new member to its senior leadership team. | Kite Pharma is flying high with ...

In 2014, Gilead launched Harvoni, which combined two antiviral drugs ... The gene therapy companies have learned some lessons from Gilead Sciences. Value-based pricing can justify the hefty ...

She has also served as a consultant and advisor for Gilead. Assessment of antiviral therapy and monitoring in mothers at the phase of immune tolerance or inactive carrier. ALT, alanine ...

When Galapagos and Gilead Sciences entered a global drug R&D collaboration ... is focusing on cell therapy, an area where Gilead already has a strong presence. Since the 2019 deal, both companies ...

Assembly Biosciences (ASMB) announced an equity investment of $20.1M by Gilead Sciences (GILD ... advance the research and development of novel antiviral therapies with $10M in accelerated ...

Jefferies analyst Michael Yee maintained a Buy rating on Gilead Sciences (GILD – Research Report) yesterday and set a price target of ...

Emerging data suggest that antiviral therapy in the third trimester can ... Pan has received research grants from Gilead, Bristol Myers Squibb, Novartis, and Roche. He also serves as a consultant ...